Allarity Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on December 7, 2021, by Allarity Therapeutics, Inc., a Delaware corporation and emerging growth company. The filing details the entry into material definitive employment agreements with three key executive officers in anticipation of the closing of a Recapitalization Share Exchange. The Company is in the process of acquiring substantially all assets and liabilities of Allarity Therapeutics A/S (Denmark) via a wholly owned subsidiary, with the transaction expected to close on or about December 20, 2021.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or liquidity data. The document focuses exclusively on executive compensation terms and the status of a pending corporate transaction.
Material Changes and Executive Compensation
On December 7, 2021, the Company entered into employment agreements with the following executives, effective December 1, 2021:
- Jens E. Knudsen (Chief Financial Officer): Annual base salary of $287,500. Eligible for an annual bonus up to 30% of base salary. Granted an incentive stock option for 18,574 shares (subject to NASDAQ listing), with 25% vesting immediately and the remainder vesting monthly over 36 months. Severance includes 4 months' pay (increasing to 6 months after the second anniversary) for termination without Cause or resignation with Good Reason, and 12 months' pay for Change-of-Control.
- James G. Cullem (SVP Corporate Development and Chief Business Officer): Annual base salary of $270,250. Eligible for an annual bonus up to 40% of base salary. Severance includes 8 months' pay for termination without Cause or resignation with Good Reason, and 12 months' pay for Change-of-Control.
- Marie Foegh, M.D. (Chief Medical Officer): Annual base salary of $331,200. Eligible for an annual bonus up to 40% of base salary. Severance includes 6 months' pay for termination without Cause or resignation with Good Reason, and 12 months' pay for Change-of-Control.
All severance payments are contingent upon the execution of a general release of claims.
Outlook, Risks, and Contingencies
The primary contingency noted is the pending completion of the Recapitalization Share Exchange, which is expected to close on or about December 20, 2021. The equity grant to the CFO is explicitly conditioned on the listing of the Company's common stock on the NASDAQ Capital Market. The filing notes that the agreements include customary confidentiality and intellectual property assignment obligations.
Key Facts for Investor Verification
- Verify the successful closing of the Recapitalization Share Exchange with Allarity Therapeutics A/S by December 20, 2021.
- Confirm the listing of Allarity Therapeutics, Inc. common stock on the NASDAQ Capital Market to trigger the CFO's equity grant.
- Review the full text of the employment agreements (Exhibits 10.1, 10.2, and 10.3) for specific definitions of "Cause," "Good Reason," and "Change-of-Control."
- Monitor future filings for the first financial results post-transaction, as this 8-K contains no historical financial data.